Systemic Inflammatory Markers for Prediction of Bevacizumab Benefit in Glioblastoma Multiforme.


Besiroglu M., Shbair A. T. , Yasin A. I. , Topcu A., Turk H. M. , Demir T.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, vol.31, pp.39-44, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31
  • Publication Date: 2021
  • Doi Number: 10.29271/jcpsp.2021.01.39
  • Title of Journal : Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • Page Numbers: pp.39-44
  • Keywords: C-reactive protein-to-albumin ratio (AR), Glioblastoma multiforme, Neutrophil-to-lymphocyteratio (NLR), Platelet-to-lymphocyte ratio (PLR), Predictive score, RESECTION

Abstract

Objective: To evaluate the predictive significance of systemic inflammation markers (SIMs) in patients with glioblastoma multiforme (GBM), who were treated with bevacizumab (Beva).